

KEY BENEFITS

Non-invasive: a simple urine sample; no DRE exam required

Actionable Results: Binary cut-point analysis that is easy to read and use

Clinically validated: Robust accuracy and sensitivity demonstrated in large, well-designed, multi-center study¹

Analyzes three biomarkers on exosomal RNA that are indicative of cancer aggressiveness

Employs expert analysis from CLIA-certified lab

Test results are available 5-7 days after specimen is received to our laboratory

This test was evaluated and its performance characteristics determined by Exosome Diagnostics Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) act of 1988 as qualified to perform high complexity clinical testing.
CLIA number—22D2093470

MKT-005 Rev. C

“Information to help discriminate high-grade prostate cancer from low grade and benign disease.”¹

¹A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

McKiernan J, Carroll P, et al.

JAMA Oncology, July 2016

²When is Prostate Cancer Really Prostate Cancer?

Bearman DM, Epstein JI. *Urol Clin North*

Am. 2014; 41(2):339-346




Exosome Diagnostics, Inc.
266 Second Ave. Suite 200
Waltham, MA 02451

(844) EXOSOME - (844) 396-7663

www.exosomedx.com

info@exosomedx.com



Valuable Information when discussing an initial prostate biopsy with your physician

EPI is a simple, non-invasive urine based liquid biopsy test


- ◇ No DRE or prostate massage needed
- ◇ No blood draw necessary
- ◇ Offers a potential “yes/no” answer to biopsy decision
- ◇ Urine collection can be at any time of the day
- ◇ Well studied in the appropriate group of men within the USA

About Prostate Cancer

Prostate cancer is the second most common cancer in men after skin cancer, and more than a quarter of a million men will be diagnosed with prostate cancer this year in the U.S. Risk factors include age, race and family history of prostate cancer.

The prostate is a walnut-sized gland, below the bladder and in front of the rectum, which produces the fluid that carries sperm. Nearly all prostate cancers begin in the gland cells that make prostate fluid. This is called an adenocarcinoma. Some prostate cancers can grow and spread quickly, but most grow very slowly. In fact, most men are likely to die of other causes before becoming symptomatic.

Early prostate cancer is generally asymptomatic while advanced prostate cancer can cause frequent urination, the feeling that the urethra is blocked and blood in the semen. However, it is important to remember that some of these symptoms also occur with benign enlargement of the prostate. If you do experience these symptoms please consult your doctor.



70-80% of biopsies are potentially unnecessary*

15% of men suffer complications related to biopsy*

3-4% of men are hospitalized within 30 days of biopsy*

* For more information please visit our website

What Does ExoDx Prostate (IntelliScore) Tell My Doctor about My Prostate Health?

This test was designed to help your doctor evaluate and rule out your risk for high-grade prostate cancer. This, in turn, may guide your medical management moving forward. The ExoDx Prostate (IntelliScore) (EPI) test can be ordered by your doctor if your PSA level is between 2-10 ng/ml. This is often called the Gray Zone because there is no clearly defined or wholly accepted protocol for next steps in your treatment. This test, in combination with other standards of care, will help your doctor decide if you are a candidate for a tissue biopsy. Evidence strongly suggests² that most prostate cancers detected are of low grade and will remain indolent throughout a patient's lifetime. This has put the medical community's focus on avoiding complications and costs associated with unnecessary biopsy and overtreatment. This test was designed to help your physician identify patients who may be able to avoid a prostate biopsy because they have a decreased likelihood of having a high-grade prostate cancer.

Frequently Asked Questions:

How do I get the EPI test?

The ExoDx Prostate (IntelliScore) must be ordered by your physician. Your physician will fill out a test requisition, collect a simple urine sample, and send the kit to our lab to perform the test.

How long does it take to get results?

The test results will be available to your physician to share with you about a week after we receive the specimen in our lab.

How much does the EPI test cost?

Exosome Diagnostics will bill your insurance company for the cost of the test, which is \$795. Our Billing Policy can be found on our website at www.exosomedx.com in the *prostate cancer* section for patients. If you are a patient outside of the United States, you will be responsible for the payment of USD \$795

Does the EPI test replace PSA testing?

No, the EPI test does not measure PSA or replace PSA testing. Your physician may use the EPI to supplement PSA testing by helping to make decisions in your prostate treatment plan.

What does my EPI score mean?

Binary Cut Point means **Actionable** results

EPI score below the cut point -
decreased risk of having High-Grade Prostate Cancer (HGPCa)¹

Possible next steps:
Continued Monitoring

EPI score above the cut point -
increased risk of having High-Grade Prostate Cancer (HGPCa)

Possible next steps:
Further evaluation or tissue biopsy